Brought to you by 
Clinigen gets European license to Theravance's antibiotic Vibativ
29 May 2015
Executive Summary
Theravance Inc. (focused on respiratory, infectious, neurological, and GI motility diseases) has licensed UK-based specialty pharmaco Clinigen Group PLC exclusive rights to commercialize the once-daily injectable antibiotic Vibativ (telavancin) in the EU and other European countries including Norway and Switzerland.
Deal Industry
- Biotechnology
- Pharmaceuticals
-
Pharmaceuticals
- Specialty Pharmaceuticals
Deal Status
- Final
Deal Type
-
Alliance
- Includes Royalty or Profit Split Information
- Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Clinigen gets European license to Theravance's antibiotic Vibativ
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice